Carmoterol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

DRUG NAME: Carmoterol

Therapeutic Class: Bronchodilator

Subclass: Long-acting β2-adrenergic agonist (LABA)

Speciality: Pulmonology

Schedule (India): Schedule H

Route(s): Inhalation

Formulations Available in India:
• Dry Powder Inhaler (DPI): 2 µg per actuation
• Available as fixed-dose combinations (FDC) with inhaled corticosteroids (budesonide, fluticasone)

Note: Limited market availability in India; verify current CDSCO status before prescribing.

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India):

1. Asthma (Maintenance Therapy — NOT for acute relief)

Parameter	Recommendation
Monotherapy	NOT recommended — must be combined with inhaled corticosteroid (ICS)
Starting dose	2 µg inhaled twice daily (as ICS+LABA FDC)
Titration	Based on ICS component and symptom control
Usual maintenance dose	2 µg twice daily
Maximum dose	4 µg twice daily
Key clinical notes	Never use without ICS; not for acute exacerbations; reassess control every 3 months

2. Chronic Obstructive Pulmonary Disease (COPD)

Parameter	Recommendation
Starting dose	2 µg inhaled twice daily
Titration	Based on symptom response and tolerability
Usual maintenance dose	2–4 µg twice daily
Maximum dose	4 µg twice daily
Key clinical notes	May be used as monotherapy or in combination with ICS/LAMA; adjust based on available formulation

Secondary Indications – Adults Only (Off-label):

No widely accepted off-label indications documented in Indian practice.

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India):

Age Group	Recommendation
<12 years	Not recommended — safety and efficacy not established
12–18 years	Use only under pulmonology specialist supervision

Note: Not first-line therapy in paediatric asthma; prefer established LABAs (formoterol, salmeterol) with more paediatric safety data.

Secondary Indications – Paediatric Doses (Off-label):

Indication	Poorly controlled asthma despite ICS alone — OFF-LABEL
Age	>12 years only
Dose	2 µg twice daily as part of ICS+LABA FDC
Duration	Ongoing with regular review
Specialist input	Required (Paediatric Pulmonology)
Evidence basis	Limited data; extrapolated from adult studies

Not recommended below 12 years except under specialist supervision.

Safety Monitoring:
• Tremors, palpitations, tachycardia
• Growth velocity monitoring with long-term use
• Baseline and periodic spirometry
• Symptom diary and peak flow tracking

RENAL ADJUSTMENT

No dose adjustment required.

Use with caution in end-stage renal disease due to limited pharmacokinetic data.

HEPATIC ADJUSTMENT

Child-Pugh Class	Recommendation
A (Mild)	No dose adjustment required
B (Moderate)	Use with caution; monitor for systemic β2-agonist effects
C (Severe)	Avoid or use under specialist supervision only — insufficient pharmacokinetic data

CONTRAINDICATIONS

• Known hypersensitivity to carmoterol or any formulation component

• Monotherapy in asthma without concurrent inhaled corticosteroid

• Acute asthma exacerbation or status asthmaticus (not a rescue medication)

• History of paradoxical bronchospasm with LABAs

CAUTIONS

• Cardiovascular disorders — arrhythmias, uncontrolled hypertension, ischaemic heart disease

• Hyperthyroidism

• Diabetes mellitus — may cause transient hyperglycaemia

• Hypokalaemia — risk increased with concurrent diuretics, corticosteroids, or xanthines

• Seizure disorders

• Lactose intolerance — some DPI formulations contain lactose as carrier

• Prolonged QTc interval

PREGNANCY

Parameter	Recommendation
Safety category	Limited human data; use with caution
Preferred alternatives	ICS alone; or ICS with salmeterol/formoterol (more established safety data in pregnancy)
When to use	Only if potential benefit justifies potential risk to fetus
Monitoring	Maternal heart rate; fetal heart rate; uterine tone (β2-agonists may affect smooth muscle)

LACTATION

Parameter	Recommendation
Compatibility	Likely compatible due to low systemic bioavailability via inhalation
Preferred alternatives	Salmeterol or formoterol (more established lactation data)
Drug levels in milk	Expected to be minimal
Infant monitoring	Feeding difficulties, irritability, tremor (rare)

ELDERLY

• Starting dose: 2 µg twice daily

• Titration: Slow, based on response and tolerability

• Additional risks: Cardiac adverse effects (tachycardia, palpitations, arrhythmias), electrolyte imbalances (hypokalaemia)

• Consider step-down therapy if high adverse effect burden or significant polypharmacy

• Monitor cardiovascular status closely

MAJOR DRUG INTERACTIONS

Interacting Drug	Mechanism / Effect	Recommendation
Non-selective β-blockers (propranolol, carvedilol)	Antagonism of bronchodilatory effect	AVOID unless strongly indicated; use cardioselective β-blockers if necessary
MAO inhibitors	Increased cardiovascular effects via catecholamine potentiation	AVOID concurrent use
Tricyclic antidepressants	Enhanced cardiovascular effects	AVOID or use with extreme caution
QT-prolonging drugs (azithromycin, fluoroquinolones, haloperidol, ondansetron)	Additive QT prolongation risk	AVOID or monitor ECG closely

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Management
Loop/thiazide diuretics	Increased risk of hypokalaemia	Monitor serum potassium
Systemic corticosteroids	Increased risk of hypokalaemia	Monitor serum potassium
Theophylline/aminophylline	Enhanced β2 effects — tachycardia, tremor	Monitor clinically; may need theophylline dose adjustment
Antidiabetic drugs	Transient hyperglycaemia may occur	Monitor blood glucose; adjust antidiabetic dose if required
Inhaled corticosteroids	Synergistic therapeutic effect	Standard combination — no dose adjustment needed

COMMON ADVERSE EFFECTS

• Tremor (fine tremor of hands)

• Palpitations

• Headache

• Throat irritation

• Cough

• Muscle cramps

• Tachycardia

SERIOUS ADVERSE EFFECTS

• Paradoxical bronchospasm — discontinue immediately and do not re-challenge

• Cardiac arrhythmias including atrial fibrillation

• QT prolongation

• Severe hypokalaemia — may cause muscle weakness, cardiac instability

• Severe hypersensitivity reactions including angioedema (rare)

• Asthma-related death (associated with LABA monotherapy without ICS)

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Spirometry/PEFR; cardiovascular assessment (HR, BP, ECG if risk factors); serum potassium; blood glucose in diabetics
After initiation/dose change	Reassess symptoms, heart rate, blood pressure within 1–2 weeks; check electrolytes if on diuretics
Long-term	Quarterly asthma/COPD control assessment; annual spirometry; periodic serum potassium in high-risk patients; ECG if symptoms suggest arrhythmia

BRANDS AVAILABLE IN INDIA

Limited market availability — verify current CDSCO-approved products before prescribing.

• FDC preparations with ICS may be available through specialty channels

• Confirm brand and formulation availability with local distributors

PRICE RANGE (INR)

• DPI preparations: ₹180–₹350 per inhaler (approximate, depending on formulation)

• FDC inhalers with ICS: ₹300–₹600 depending on ICS strength and brand

• Not listed under NLEM; prices not NPPA-controlled

CLINICAL PEARLS

• Never prescribe carmoterol as monotherapy in asthma — always combine with inhaled corticosteroid to reduce risk of asthma-related mortality

• Has faster onset of action compared to salmeterol but less established clinical experience than formoterol

• Use lowest effective dose to minimise β-agonist adverse effects, particularly in elderly and those with cardiovascular comorbidities

• Monitor potassium levels closely in patients on diuretics, systemic corticosteroids, or with cardiac disease

• Consider more established LABAs (formoterol, salmeterol) as first-line unless specific patient factors favour carmoterol

• Ensure proper inhaler technique training — common cause of apparent treatment failure

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.